Credit Suisse Reiterates Outperform on Avidity Biosciences, Maintains $30 Price Target
Portfolio Pulse from richadhand@benzinga.com
Credit Suisse analyst Judah Frommer has reiterated an 'Outperform' rating on Avidity Biosciences (NASDAQ:RNA) and maintained a $30 price target.
August 09, 2023 | 12:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Credit Suisse has reiterated an 'Outperform' rating on Avidity Biosciences and maintained a $30 price target.
The reiteration of an 'Outperform' rating by Credit Suisse indicates a positive outlook for Avidity Biosciences. The maintained price target of $30 suggests that the analyst believes the stock is still undervalued, which could lead to upward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100